FCGR2B and melanoma: Finally, although this review has largely focussed on the context of B cell targets, there is also evidence that CD32B is expressed by other target cells (e.g. metastatic melanoma cells), and a mechanism whereby CD32B inhibits ADCC of these cells has also been proposed [47] providing the potential for therapeutic blocking of CD32B in this setting.